Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView have announced a groundbreaking collaboration to launch the first integrated AI and genetic risk platform for personalized breast health. The new offering combines genetic testing, artificial intelligence, and clinical workflow tools to help identify women at the highest risk for breast cancer earlier and more accurately, enabling more timely and individualized interventions. The platform brings together three key components: Myriad’s MyRisk Hereditary Cancer Test with RiskScore, which assesses inherited genetic risk; Clairity’s AI-powered Clairity Breast, the first and only FDA-authorized tool that estimates a woman’s five-year breast cancer risk directly from a routine mammogram; and MagView’s Luminary Risk platform, a leading breast imaging workflow solution used by over 2,500 facilities across the U.S., including many top cancer centers. By integrating these technologies into a single, seamless system, clinicians can now access a comprehensive, real-time view of both a patient’s genetic and phenotypic risk factors. This integration eliminates the need for separate data entry and analysis, reducing administrative burden while improving the accuracy and actionability of risk assessments. Jeff Luber, CEO of Clairity, said the platform marks a major step forward in shifting breast cancer care from detection to prevention. “Using AI-powered risk assessment, Clairity Breast identifies women at the highest risk from a routine mammogram,” he said. “By combining this with genetic data, we give clinicians a much more complete picture of individual risk than ever before.” Sam Raha, President and CEO of Myriad Genetics, emphasized the importance of early, personalized care. “Effective screening of individuals with elevated risk of cancer is an important part of the cancer care continuum,” he said. “By pairing the MyRisk test with Clairity’s AI-powered risk assessment within MagView’s workflow, we aim to empower clinicians with actionable results, helping to enable earlier, more personalized interventions.” Bryan Chapin, President and CEO of MagView, highlighted the platform’s ability to streamline clinical operations. “Our platform streamlines how risk information is captured, interpreted, and acted on,” he said. “Integrating Clairity and MyRisk into one system gives providers a powerful, unified tool to support proactive breast health management, while improving workflow efficiency and patient experience.” The collaboration is designed to help health systems and radiologists better target high-risk patients for enhanced screening, risk-reducing strategies, and early treatment. By combining genomics with AI-driven imaging analysis, the platform aims to improve outcomes, reduce unnecessary procedures, and lower the long-term cost of cancer care. The integrated solution is now available to facilities using MagView’s Luminary Risk platform, with plans to expand access in the coming months. The companies believe this represents a transformative step in the fight against breast cancer, moving toward a future where care is truly personalized, preventive, and data-driven.